Sysmex Europe
Menu

Plasma-SeqSensei™ Solid Cancer IVD Kit

Sensitive mutation detection and streamlined workflow

Plasma-SeqSenseiTM assays enable highly sensitive and quantitative detection of mutations in circulating tumour DNA (ctDNA) from the blood plasma of cancer patients by utilising next-generation sequencing technology. Plasma-SeqSenseiTM's short and standardised workflow delivers results within two days, including the generation of easy-to-read reports using laptop-compatible Plasma-SeqSenseiTM IVD Software.

The kit covers key gene mutations on BRAF, EGFR, KRAS, NRAS and PIK3CA to detect established and emerging predictive markers, resistance mutations and frequently occurring genetic alterations in cancer.

Plasma-SeqSenseiTM Solid Cancer IVD Kit is intended to support clinicians with:

  • detecting minimal residual disease
  • recurrence surveillance
  • (neo-)adjuvant response monitoring
  • analysing the RAS mutation status to determine the potential benefit of anti-epidermal growth factor receptor (EGFR) therapy for colorectal cancer patients
More details

Gene targets

Gene Transcript1 Amino acid start Amino acid end Most frequent mutations detected (AA change)2
BRAF ENST00000288602.6 462 477 G469A/R/V/E, G466V/E
BRAF ENST00000288602.6 582 604 V600E/K/R/M, K601E, D594G
EGFR ENST00000275493.2 706 725 G719A/S
EGFR ENST00000275493.2 743 759 E746_A750del, L747_P753delinsS, L747_T751del, L747_A750delinsP, E746_S752delinsV
EGFR ENST00000275493.2 762 775 S768I
EGFR ENST00000275493.2 788 801 T790M
EGFR ENST00000275493.2 856 873 L858R, L861Q
KRAS ENST00000256078.4 12 34 G12D/V/C/A/S/R/F, G13D/C/R/V/A
KRAS ENST00000256078.4 57 76 Q61H/R/L/H/K, A59T
KRAS ENST00000256078.4 110 117 K117N
KRAS ENST00000256078.4 141 148 A146T/V
NRAS ENST00000369535.4 1 17 G12D/C/S/A/V/R, G13R/V/C/S
NRAS ENST00000369535.4 55 70 Q61R/K/L/H
NRAS ENST00000369535.4 115 121 L120D, K117R
NRAS ENST00000369535.4 141 149 A146V/T
PIK3CA ENST00000263967.3 538 553 E545K/A/G/Q, E542K, Q546K/R/P
PIK3CA ENST00000263967.3 1,040 1,065 H1047R/L/Y, G1049R, M1043I/V

 

1 Sequence source: Ensemble database

2 For the exact nucleotide coverage refer to the Plasma-SeqSenseiTM Instruction for Use

Technical specifications
Feature Plasma-SeqSensei™ Solid Cancer IVD Kit
Sample type Whole blood and plasma
Sample capacity

2–16 samples per kit and up to 32 samples with Plasma-SeqSenseiTM Extension IVD Kit

QC function Positive control and no template control (NTC) applied to every run
Compatible platforms Illumina NextSeq 500/550TM
Input DNA required 5.7–95 ng/116 µl
Number of amplicons 17
Sensitivity 0.07% allele frequency at 95% certainty at 10,000 wildtype copies
Cut-off 7 mutant molecules
Cat. No. ZR150534

 

Contact us
You have a question and would like to get in touch with our experts? We look forward to receiving your enquiry.

Sysmex Europe SE

Bornbarch 1

22848 Norderstedt

Germany

+49 (40) 527 26 0

+49 (40) 527 26 100

Training

Plasma-SeqSenseiTM basic online training

After completing this course, you will be able to perform liquid biopsy analyses using Plasma-SeqSenseiTM Kits. This training is intended for laboratory specialists who will perform liquid biopsy analyses using Plasma-SeqSenseiTM Kits.

Course page

Documents

Product documents

Regulatory documents

Regulatory documents, such as Instructions for Use, can be accessed with a valid My Sysmex login:

Go to My Sysmex

Explore more

Plasma-SeqSensei™ Breast Cancer IVD Kit

Plasma-SeqSensei™ Breast Cancer IVD Kit

Plasma-SeqSenseTM Breast Cancer IVD Kit

Details
Plasma-SeqSensei™ Colorectal Cancer RUO Kit

Plasma-SeqSensei™ Colorectal Cancer RUO Kit

Plasma-SeqSensei™ CRC RUO Kit

Details
Plasma-SeqSensei™ Non-Small Cell Lung Cancer RUO Kit

Plasma-SeqSensei™ Non-Small Cell Lung Cancer RUO Kit

Plasma-SeqSensei™ NSCLC RUO Kit

Details
Copyright © Sysmex Europe SE. All rights reserved.